The purpose of this study is to determine the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).

Clinical Program: Melanoma and Cutaneous Oncology Program
Primary Sponsor: Merck
Contact Info: 202-741-3379